Ninety percent of the hardest patients to transplant still had functioning kidneys at one year — and that single number, drawn from 51 highly sensitized adults across 22 centers in 11 countries, is now the evidentiary backbone of Hansa Biopharma’s bid to convert Idefirix from conditional to full EMA marketing authorization.
The design context matters here. Highly sensitized patients carry preformed donor-specific antibodies that make a positive crossmatch the default outcome against most available deceased donors. Imlifidase cleaves IgG antibodies within hours of administration, temporarily flipping that crossmatch to negative and opening a transplant window that would otherwise stay shut — often indefinitely. The PAES enrolled only patients who met that threshold of immunological difficulty, which makes the 90% graft failure-free survival at one year a genuine signal rather than an artifact of patient selection. Graft survival reached 92%, patient survival 98%, and mean eGFR landed at 52.4 mL/min/1.73 m² — functional kidney performance, not just graft persistence. Patient retention above 94% in a multinational open-label study is also worth noting; dropout is where post-authorization studies routinely lose their credibility with regulators.
The regulatory mechanics are straightforward but consequential. Conditional authorization in the EU obligates sponsors to complete specific post-authorization studies as a condition of maintaining market access. Fulfilling that obligation doesn’t guarantee full authorization, but failure would have triggered the inverse. Hansa now has the clean confirmatory data the EMA required, and the Q4 2026 submission timeline is tight enough that a 2027 decision is plausible. Full authorization removes the annual renewal burden, broadens labeling stability, and — critically for a rare-disease product — provides the commercial and reimbursement durability that health technology assessment bodies in Germany, France, and the UK have historically required before committing to sustained coverage of high-cost interventions.
The number to watch is the EMA’s formal validation of the full authorization submission, expected after Q4 2026 filing. Rejection or a request for additional data at that stage would reset Hansa’s reimbursement negotiations across multiple European markets simultaneously — a concentrated risk that the 90% efficacy figure, however clean, does not fully insulate against.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
